



# MMV's mission

- In response to a virtually empty malaria drug pipeline, MMV was established in 1999
- Mission: discover, develop and deliver innovative, effective and affordable antimalarial drugs
- It is a product development partnership (PDP), raising public, private and philanthropic resources to support the most promising R&D on antimalarials.
- Over 160 active partners across 50 countries











10 REDUCED INEQUALITIES



### Malaria elimination: contribution to SDGs



#### SDG<sub>1</sub>

end poverty in all its forms, everywhere

#### SDG<sub>3</sub>

ensure healthy lives and promote well-being: **3.1** reduce global maternal mortality; **3.2** end preventable deaths of newborns & children <5 years;

**3.3** by 2030, end epidemics of AIDS,TB, malaria.

#### SDG 8

promote sustained, inclusive and sustainable economic growth

#### **SDG 17**

partnerships for the goals



### Impact of malaria control

#### SDG<sub>1</sub>

10% reduction in malaria provides a 0.3% rise in annual GDP <sup>1</sup>

#### SDG<sub>3</sub>

achieving SDG 3.3 for malaria will avert 3 billion malaria cases, saving around 10 million lives², including around 7 million children <5 years and tens of thousands of pregnant women

#### SDG8

reducing malaria creates healthier, more productive workforces: return on investment 36:1<sup>3</sup>; cumulative ROI 2016-2030 \$4.1 trillion<sup>2</sup>

#### **SDG 17**

130 partnerships spanning 47 countries: across public and private sectors; providing investment, know-how, capacity building & new lifesaving medicines

16 PEACE, JUSTIC AND STRONG INSTITUTIONS

13 CLIMATE ACTION



1. Gallup JL, Sachs J (2001). The economic burden of malaria. Amer J Trop Med Hyg; 64 (1,2) S: 85-96. 2. Investing for a malaria-free world. Action and investment to defeat malaria 2016-2030 WHO Roll Back Malaria (RBM) Partnership 2015. 3. Swiss Tropical and Public Health Institute in collaboration with Deloitte.

### From MDGs to the 2030 Agenda

#### Last 15 years (2000-2015) MMV's Malaria-related Millennium Development Goals 4, 5 & 6 contribution 1999 MMV launched >6.2 M lives saved 65% to develop 60% decline in malaria-related deaths drop in for vulnerable child 2008 Coartem® Dispersible mortality (partner Novartis) (>5 years) child-friendly ACTs from 2010 Guilin's Artesun® malaria for severe malaria Eurartesim<sup>6</sup> Funding increased 20x for uncomplicated 2000-2013: malaria (partner 2012 Pyramax® for uncomplicated malaria (partner Shin Poong) 2000 **USD 130** 2014 Guilin's SP+AQ for million chemoprevention 2013 **57** countries 2015 Pyramax® Granules USD 2.7 to treat children (partner Shin Poong) have reduced malaria cases by >75% ■ Malaria free billion MMV's Today malaria remains a killer disease contribution 250 million courses of Coartem® Dispersible 438,000 lives delivered to treat children in 50 countries lost to malaria, the majority (71%)- 36 million vials of Artesun® delivered, African children under 5 and saved an estimated 200,000-240,000 lives \*\*\*\*\*\*\*\*\*\* compared to treatment 15 countries mainly in Africa, account for 80% of cases and 78% of deaths 3.2 B at risk Malaria remains a maior cause and consequence of poverty Next 15 years (2016-2030) MMV's goals Reduce global case Eliminate malaria in Launch new pediatric WHO goals ACTs in endemic incidence and deaths 35 more countries countries by 90% Develop single dose compliance to treatment Global funding needs for malaria and tackle resistance Identify alternative Annual funding will need to triple 100 B+ over the next 15-year period, from n for pregnant women to achieve Develop new options to 2013 goal ····· USD 2.7 billion + USD Develop drugs to 2030 10 B USD 8.7 billion for R&D of

Elimination needs more funding from international donors and

affected countries



## Addressing unmet medical needs



**RESISTANCE** in Asia. risk to spread globally



**CHILDREN** 

**& PREGNANT** 

**Medicines better** 

suited

to special

needs

WOMEN

**CURES** 

**Simplify** 

treatments

for

better adherence



**PREVENTION** SINGLE DOSE **OF RELAPSE** Recurrent/seasonal malaria



**TRANSMISSION BLOCKING** to protect non-immune populations and move to elimination




**CHEMO PREVENTION** waiting for/ complementing vaccine

## Leave no one behind

Continued focus on vulnerable groups: children, pregnant women, underserved populations

## **Children matter**





4. pyronaridine-artesunate